Krystal Biotech (KRYS) Cash from Operations (2016 - 2026)

Krystal Biotech has reported Cash from Operations for 11 years, with the latest figure at 74789000.0 in Q2 2026.

• Cash from Operations for Q2 2026 came in at 74789000.0, up 41.84% year-over-year; the trailing twelve-month figure through Jun 2026 was 272338000.0 (up 39.38% YoY), and the FY2025 annual result was 200865000.0, up 62.75% from the prior year.
• Cash from Operations fell to 74789000.0 in Q2 2026, from 80382000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 80382000.0 in Q1 2026 and troughed at 43059000.0 in Q2 2022.
• A 5-year average of 16115722.22 and a median of 5860000.0 in 2024 frame the typical range for Cash from Operations.
• The widest annual swing landed in 2022, when Cash from Operations tumbled 325.11%; it then surged 1365.09% in 2025.
• A 5-year view of Cash from Operations shows it stood at 22329000.0 in 2022, then jumped by 67.61% to 7232000.0 in 2023, then jumped by 830.68% to 52843000.0 in 2024, then surged by 46.68% to 77508000.0 in 2025, then declined by 3.51% to 74789000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 74789000.0 in Q2 2026, 80382000.0 in Q1 2026, and 77508000.0 in Q4 2025.